EP2958550 - ORAL FORMULATION AND SUSPENSION OF AN ONCOLOGY DRUG [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 23.06.2023 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 15.07.2022 | ||
Former | Grant of patent is intended Status updated on 22.02.2022 | ||
Former | Examination is in progress Status updated on 03.12.2019 | Most recent event Tooltip | 16.02.2024 | Lapse of the patent in a contracting state New state(s): BE | published on 20.03.2024 [2024/12] | Applicant(s) | For all designated states Sun Pharmaceutical Industries Limited SPARC, TANDALJA Vadodara, Gujarat-390012 / IN | [2022/32] |
Former [2019/01] | For all designated states Sun Pharma Global FZE 43, Block Y, SAIF Zone P.O. Box 122304 Sharjah / AE | ||
Former [2016/01] | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | Inventor(s) | 01 /
DECAUDIN, Céline c/o Novartis Pharma AG Novartis Campus Virchow 6-4th 4056 Basel / CH | 02 /
ROGUE, Vincent c/o Novartis Pharma AG Forum 1 Novartis Campus 4056 Basel / CH | [2022/33] |
Former [2016/01] | 01 /
DECAUDIN, Celine c/o Novartis Pharma AG Forum 1 Novartis Campus CH-4056 Basel / CH | ||
02 /
ROGUE, Vincent c/o Novartis Pharma AG Forum 1 Novartis Campus CH-4056 Basel / CH | Representative(s) | HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB | [2022/33] |
Former [2016/01] | Rudge, Sewkian Novartis Pharma AG Patent Department 4002 Basel / CH | Application number, filing date | 14710642.1 | 21.02.2014 | [2016/01] | WO2014IB59161 | Priority number, date | US201361768803P | 25.02.2013 Original published format: US 201361768803 P | [2016/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014128661 | Date: | 28.08.2014 | Language: | EN | [2014/35] | Type: | A1 Application with search report | No.: | EP2958550 | Date: | 30.12.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 28.08.2014 takes the place of the publication of the European patent application. | [2015/53] | Type: | B1 Patent specification | No.: | EP2958550 | Date: | 17.08.2022 | Language: | EN | [2022/33] | Search report(s) | International search report - published on: | EP | 28.08.2014 | Classification | IPC: | A61K9/10, A61K47/14, A61K31/5377, A61P35/00 | [2022/10] | CPC: |
A61K31/5377 (EP,IL,US);
A61K47/02 (IL,US);
A61K47/12 (IL,US);
A61K47/14 (EP,IL,US);
A61K47/26 (IL,US);
A61K47/38 (IL,US);
A61K9/0095 (EP,IL,US);
A61K9/10 (EP,IL,US);
A61P35/00 (EP,IL);
B65D81/32 (IL,US)
(-)
|
Former IPC [2016/01] | A61K9/10, A61K47/14, A61K31/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/01] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | ORALE FORMULIERUNG UND SUSPENSION EINES ONKOLOGISCHEN ARZNEIMITTELS | [2016/01] | English: | ORAL FORMULATION AND SUSPENSION OF AN ONCOLOGY DRUG | [2016/01] | French: | FORMULATION ET SUSPENSION À USAGE ORAL D'UN MÉDICAMENT ONCOLOGIQUE | [2016/01] | Entry into regional phase | 25.09.2015 | National basic fee paid | 25.09.2015 | Designation fee(s) paid | 25.09.2015 | Examination fee paid | Examination procedure | 02.09.2015 | Amendment by applicant (claims and/or description) | 25.09.2015 | Examination requested [2015/53] | 06.12.2019 | Despatch of a communication from the examining division (Time limit: M06) | 07.06.2020 | Reply to a communication from the examining division | 26.05.2021 | Despatch of a communication from the examining division (Time limit: M04) | 05.10.2021 | Reply to a communication from the examining division | 23.02.2022 | Communication of intention to grant the patent | 05.07.2022 | Fee for grant paid | 05.07.2022 | Fee for publishing/printing paid | 05.07.2022 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 06.12.2019 | Opposition(s) | 19.05.2023 | No opposition filed within time limit [2023/30] | Fees paid | Renewal fee | 10.02.2016 | Renewal fee patent year 03 | 10.02.2017 | Renewal fee patent year 04 | 27.02.2018 | Renewal fee patent year 05 | 28.02.2019 | Renewal fee patent year 06 | 02.03.2020 | Renewal fee patent year 07 | 25.02.2021 | Renewal fee patent year 08 | 25.02.2022 | Renewal fee patent year 09 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 17.08.2022 | AT | 17.08.2022 | CZ | 17.08.2022 | DK | 17.08.2022 | EE | 17.08.2022 | FI | 17.08.2022 | HR | 17.08.2022 | LT | 17.08.2022 | LV | 17.08.2022 | MC | 17.08.2022 | RS | 17.08.2022 | SE | 17.08.2022 | SI | 17.08.2022 | SK | 17.08.2022 | SM | 17.08.2022 | NO | 17.11.2022 | GR | 18.11.2022 | IS | 17.12.2022 | PT | 19.12.2022 | IE | 21.02.2023 | LU | 21.02.2023 | BE | 28.02.2023 | [2024/12] |
Former [2024/08] | AL | 17.08.2022 | |
AT | 17.08.2022 | ||
CZ | 17.08.2022 | ||
DK | 17.08.2022 | ||
EE | 17.08.2022 | ||
FI | 17.08.2022 | ||
HR | 17.08.2022 | ||
LT | 17.08.2022 | ||
LV | 17.08.2022 | ||
MC | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
SI | 17.08.2022 | ||
SK | 17.08.2022 | ||
SM | 17.08.2022 | ||
NO | 17.11.2022 | ||
GR | 18.11.2022 | ||
IS | 17.12.2022 | ||
PT | 19.12.2022 | ||
IE | 21.02.2023 | ||
LU | 21.02.2023 | ||
Former [2023/49] | AL | 17.08.2022 | |
AT | 17.08.2022 | ||
CZ | 17.08.2022 | ||
DK | 17.08.2022 | ||
EE | 17.08.2022 | ||
FI | 17.08.2022 | ||
HR | 17.08.2022 | ||
LT | 17.08.2022 | ||
LV | 17.08.2022 | ||
MC | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
SI | 17.08.2022 | ||
SK | 17.08.2022 | ||
SM | 17.08.2022 | ||
NO | 17.11.2022 | ||
GR | 18.11.2022 | ||
IS | 17.12.2022 | ||
PT | 19.12.2022 | ||
LU | 21.02.2023 | ||
Former [2023/44] | AL | 17.08.2022 | |
AT | 17.08.2022 | ||
CZ | 17.08.2022 | ||
DK | 17.08.2022 | ||
EE | 17.08.2022 | ||
FI | 17.08.2022 | ||
HR | 17.08.2022 | ||
LT | 17.08.2022 | ||
LV | 17.08.2022 | ||
MC | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
SI | 17.08.2022 | ||
SK | 17.08.2022 | ||
SM | 17.08.2022 | ||
NO | 17.11.2022 | ||
GR | 18.11.2022 | ||
IS | 17.12.2022 | ||
PT | 19.12.2022 | ||
Former [2023/37] | AL | 17.08.2022 | |
AT | 17.08.2022 | ||
CZ | 17.08.2022 | ||
DK | 17.08.2022 | ||
EE | 17.08.2022 | ||
FI | 17.08.2022 | ||
HR | 17.08.2022 | ||
LT | 17.08.2022 | ||
LV | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
SI | 17.08.2022 | ||
SK | 17.08.2022 | ||
SM | 17.08.2022 | ||
NO | 17.11.2022 | ||
GR | 18.11.2022 | ||
IS | 17.12.2022 | ||
PT | 19.12.2022 | ||
Former [2023/29] | AL | 17.08.2022 | |
AT | 17.08.2022 | ||
CZ | 17.08.2022 | ||
DK | 17.08.2022 | ||
EE | 17.08.2022 | ||
FI | 17.08.2022 | ||
HR | 17.08.2022 | ||
LT | 17.08.2022 | ||
LV | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
SK | 17.08.2022 | ||
SM | 17.08.2022 | ||
NO | 17.11.2022 | ||
GR | 18.11.2022 | ||
IS | 17.12.2022 | ||
PT | 19.12.2022 | ||
Former [2023/23] | AT | 17.08.2022 | |
CZ | 17.08.2022 | ||
DK | 17.08.2022 | ||
EE | 17.08.2022 | ||
FI | 17.08.2022 | ||
HR | 17.08.2022 | ||
LT | 17.08.2022 | ||
LV | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
SK | 17.08.2022 | ||
SM | 17.08.2022 | ||
NO | 17.11.2022 | ||
GR | 18.11.2022 | ||
IS | 17.12.2022 | ||
PT | 19.12.2022 | ||
Former [2023/22] | AT | 17.08.2022 | |
CZ | 17.08.2022 | ||
DK | 17.08.2022 | ||
FI | 17.08.2022 | ||
HR | 17.08.2022 | ||
LT | 17.08.2022 | ||
LV | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
SM | 17.08.2022 | ||
NO | 17.11.2022 | ||
GR | 18.11.2022 | ||
IS | 17.12.2022 | ||
PT | 19.12.2022 | ||
Former [2023/21] | DK | 17.08.2022 | |
FI | 17.08.2022 | ||
HR | 17.08.2022 | ||
LT | 17.08.2022 | ||
LV | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
SM | 17.08.2022 | ||
NO | 17.11.2022 | ||
GR | 18.11.2022 | ||
IS | 17.12.2022 | ||
PT | 19.12.2022 | ||
Former [2023/20] | FI | 17.08.2022 | |
HR | 17.08.2022 | ||
LT | 17.08.2022 | ||
LV | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
SM | 17.08.2022 | ||
NO | 17.11.2022 | ||
GR | 18.11.2022 | ||
IS | 17.12.2022 | ||
PT | 19.12.2022 | ||
Former [2023/12] | FI | 17.08.2022 | |
HR | 17.08.2022 | ||
LT | 17.08.2022 | ||
LV | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
NO | 17.11.2022 | ||
GR | 18.11.2022 | ||
IS | 17.12.2022 | ||
PT | 19.12.2022 | ||
Former [2023/10] | FI | 17.08.2022 | |
HR | 17.08.2022 | ||
LT | 17.08.2022 | ||
LV | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
NO | 17.11.2022 | ||
GR | 18.11.2022 | ||
PT | 19.12.2022 | ||
Former [2023/09] | FI | 17.08.2022 | |
LT | 17.08.2022 | ||
LV | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
NO | 17.11.2022 | ||
PT | 19.12.2022 | ||
Former [2023/08] | FI | 17.08.2022 | |
LT | 17.08.2022 | ||
RS | 17.08.2022 | ||
SE | 17.08.2022 | ||
NO | 17.11.2022 | Cited in | International search | [XY]WO2010033481 (NOVARTIS AG [CH], et al) [X] 1,17 * page 2, paragraph 0005 * * examples 4, 10 * [Y] 1-3,17; | [Y]US2012122866 (FRITZE ANDREAS [DE], et al) [Y] 1-3,17 * page 1, paragraph 0001 * * page 2, paragraph 0021 - page 4, paragraph 0063 ** page 6, paragraphs 0099-0100 * | by applicant | WO2007US68292 |